Literature DB >> 8872908

Active and passive experimental autoimmune encephalomyelitis in strain 129/J (H-2b) mice.

R B Fritz1, M L Zhao.   

Abstract

Failure of C57BL/6J and C57BL/10Sn (H-2b) mice to exhibit clinical signs of experimental autoimmune encephalomyelitis following immunization with myelin basic protein (MBP) has been interpreted to indicate that mice of this haplotype are resistant to EAE. Recently, we immunized strain 129/J (H-2b) mice with rat MBP and found that clinical signs of EAE were expressed in the majority of animals within 2 to 3 weeks. Passive EAE was readily induced by adoptive transfer of MBP-specific T cell lines to syngeneic recipients. MBP peptide 89-101 and PLP peptide 178-191 induced EAE upon active immunization although proteolipid protein peptide 139-151 was ineffective in this regard. Strain 129/J mice never recovered fully from acute EAE, and signs of relapsing disease were not observed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8872908     DOI: 10.1002/(SICI)1097-4547(19960815)45:4<471::AID-JNR17>3.0.CO;2-3

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  9 in total

1.  MP4- and MOG:35-55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum.

Authors:  Stefanie Kuerten; Dilyana A Kostova-Bales; Lukas P Frenzel; Justine T Tigno; Magdalena Tary-Lehmann; Doychin N Angelov; Paul V Lehmann
Journal:  J Neuroimmunol       Date:  2007-07-25       Impact factor: 3.478

Review 2.  SLAM family receptors and the SLAM-associated protein (SAP) modulate T cell functions.

Authors:  Cynthia Detre; Marton Keszei; Xavier Romero; George C Tsokos; Cox Terhorst
Journal:  Semin Immunopathol       Date:  2010-02-10       Impact factor: 9.623

3.  PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis.

Authors:  Vimal Selvaraj; Mangala M Soundarapandian; Olga Chechneva; Ambrose J Williams; Maxim K Sidorov; Athena M Soulika; David E Pleasure; Wenbin Deng
Journal:  J Biol Chem       Date:  2009-07-23       Impact factor: 5.157

4.  Multiantigen/multiepitope-directed immune-specific suppression of "complex autoimmune encephalomyelitis" by a novel protein product of a synthetic gene.

Authors:  Ming-Chao Zhong; Nicole Kerlero de Rosbo; Avraham Ben-Nun
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

5.  Fundamental differences in the dynamics of CNS lesion development and composition in MP4- and MOG peptide 35-55-induced experimental autoimmune encephalomyelitis.

Authors:  Stefanie Kuerten; Sita Javeri; Magdalena Tary-Lehmann; Paul V Lehmann; Doychin N Angelov
Journal:  Clin Immunol       Date:  2008-08-23       Impact factor: 3.969

6.  'Multi-epitope-targeted' immune-specific therapy for a multiple sclerosis-like disease via engineered multi-epitope protein is superior to peptides.

Authors:  Nathali Kaushansky; Nicole Kerlero de Rosbo; Rina Zilkha-Falb; Reut Yosef-Hemo; Lydia Cohen; Avraham Ben-Nun
Journal:  PLoS One       Date:  2011-11-29       Impact factor: 3.240

7.  Regulatory lymphocytes are key factors in MHC-independent resistance to EAE.

Authors:  Nieves Marín; Miriam Mecha; Carmen Espejo; Leyre Mestre; Herena Eixarch; Xavier Montalban; José C Álvarez-Cermeño; Carmen Guaza; Luisa M Villar
Journal:  J Immunol Res       Date:  2014-04-27       Impact factor: 4.818

8.  Epitope-Specific Tolerance Modes Differentially Specify Susceptibility to Proteolipid Protein-Induced Experimental Autoimmune Encephalomyelitis.

Authors:  Lei Wang; Julia Winnewisser; Christine Federle; Gregor Jessberger; Klaus-Armin Nave; Hauke B Werner; Bruno Kyewski; Ludger Klein; Maria Hinterberger
Journal:  Front Immunol       Date:  2017-11-09       Impact factor: 7.561

Review 9.  Therapeutic Potentials of Poly (ADP-Ribose) Polymerase 1 (PARP1) Inhibition in Multiple Sclerosis and Animal Models: Concept Revisiting.

Authors:  Yan Wang; David Pleasure; Wenbin Deng; Fuzheng Guo
Journal:  Adv Sci (Weinh)       Date:  2021-12-21       Impact factor: 17.521

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.